Clinical data | |
---|---|
Trade names | Glyset |
AHFS/Drugs.com | Monograph |
MedlinePlus | a601079 |
License data | |
Pregnancy category |
|
Routes of administration | By mouth (tablets) |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | Dose-dependent |
Protein binding | Negligible (<4.0%) |
Metabolism | Nil |
Elimination half-life | 2 hours |
Excretion | Renal (95%) |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.069.670 |
Chemical and physical data | |
Formula | C8H17NO5 |
Molar mass | 207.226 g·mol−1 |
3D model (JSmol) | |
Density | 1.458 g/cm3 |
Melting point | 114 °C (237 °F) |
| |
| |
(verify) |
Miglitol is an oral anti-diabetic drug that acts by inhibiting the ability of the patient to break down complex carbohydrates into glucose. It is primarily used in diabetes mellitus type 2 for establishing greater glycemic control by preventing the digestion of carbohydrates (such as disaccharides, oligosaccharides, and polysaccharides) into monosaccharides which can be absorbed by the body.[1]
Miglitol, and other structurally-related iminosugars, inhibit glycoside hydrolase enzymes called alpha-glucosidases. Since miglitol works by preventing digestion of carbohydrates, it lowers the degree of postprandial hyperglycemia. It must be taken at the start of main meals to have maximal effect.[2] Its effect will depend on the amount of non-monosaccharide carbohydrates in a person's diet.
In contrast to acarbose (another alpha-glucosidase inhibitor), miglitol is systemically absorbed; however, it is not metabolized and is excreted by the kidneys.